Chronoscale Corporation (CHRN)
NASDAQ:CHRN
Want to see CHRN full AI Analyst Report?
Top Page
ChronoScale
(NASDAQ:CHRN)
Select Model
Select Model
Rating:52Neutral
Price Target:
$19.00
▲(87.19% Upside)
Action:Reiterated
Date:06/06/26
The score is held back primarily by weak financial performance—large losses, ongoing cash burn, and a shrinking equity cushion—despite healthy gross margins. Technicals are a key offset, with strong multi-timeframe uptrend and supportive momentum. Valuation remains constrained by unprofitability, and the announced divestiture adds additional near-term uncertainty due to unquantified restructuring charges.
Positive Factors
High Gross Margins
Sustained product-level gross margins (~50–60% TTM, ~53% reported) indicate structurally strong unit economics. This provides room to cover operating leverage as revenue scales, improving the path to durable profitability if topline stabilizes or SG&A is optimized.
Negative Factors
Deep Unprofitability
A net margin near -91% and very large operating losses reflect a prolonged inability to convert strong gross margins into operating profitability. Persistent losses erode capital and require sustained operational improvement or new revenue streams to achieve financial sustainability over months.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained product-level gross margins (~50–60% TTM, ~53% reported) indicate structurally strong unit economics. This provides room to cover operating leverage as revenue scales, improving the path to durable profitability if topline stabilizes or SG&A is optimized.
Read all positive factors
ChronoScale Key Performance Indicators (KPIs)
ChronoScale (CHRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.72B
Dividend YieldN/A
Average Volume (3M)317.55K
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth-34.08%
EPS Growth26.18%
CountryUS
Employees55
SectorTechnology
Sector Strength88
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-5.39
Shares Outstanding143,093,380
10 Day Avg. Volume403,969
30 Day Avg. Volume317,548
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.32
Price to Sales (P/S)1.64
P/FCF Ratio-1.75
Enterprise Value/Market Cap0.01
Enterprise Value/Revenue2.47
Enterprise Value/Gross Profit4.68
Enterprise Value/Ebitda-2.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$19.38M
ChronoScale Business Overview & Revenue Model
Company Description
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered ...
ChronoScale Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
14
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
ChronoScale Technical Analysis
Positive
10.15
Price Trends
13.27
Positive
11.65
Positive
8.33
Positive
Market Momentum
1.87
Negative
58.32
Neutral
75.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRN, the sentiment is Positive. The current price of 10.15 is below the 20-day moving average (MA) of 16.94, below the 50-day MA of 13.27, and above the 200-day MA of 8.33, indicating a bullish trend. The MACD of 1.87 indicates Negative momentum. The RSI at 58.32 is Neutral, neither overbought nor oversold. The STOCH value of 75.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CHRN.
ChronoScale Risk Analysis
ChronoScale disclosed 39 risk factors in its most recent earnings report. ChronoScale reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ChronoScale Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
52 Neutral | $2.72B | -2.65 | -177.40% | ― | -34.08% | 26.18% | |
49 Neutral | $27.94M | -2.83 | -73.04% | ― | -6.42% | 83.35% | |
49 Neutral | $36.58M | -7.46 | -166.28% | ― | 3.37% | 15.78% | |
44 Neutral | $5.81M | -0.70 | -74.10% | ― | 74.57% | 60.81% |
* Technology Sector Average
CHRN
ChronoScale
19.03
14.72
341.53%
HBIO
Harvard Bioscience
6.20
0.61
10.96%
MLSS
Milestone Scientific
0.42
-0.49
-54.30%
LUCY
Innovative Eyewear, Inc.
0.91
-1.92
-67.92%
ChronoScale Corporate Events
Business Operations and StrategyM&A Transactions
ChronoScale Divests Ekso Bionics to Refocus on Cloud
Negative
Jun 4, 2026
On May 29, 2026, ChronoScale Corporation’s board approved a plan to divest its wholly owned subsidiary Ekso Bionics, Inc., which had not previously been disclosed as held for sale. The move marks a strategic pivot to focus the company’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.